Company Overview
Rapid Micro Biosystems, Inc. operates as a life sciences technology company dedicated to providing products for the detection of microbial contamination across the manufacturing of pharmaceuticals, biologics, medical devices, and personal care products. This operational focus places the entity within the Healthcare sector, specifically the Medical Devices industry, where it serves markets including the United States, Switzerland, Germany, Japan, and various international locations. The company currently maintains a market capitalization of $100.02M and employs 171 individuals to support its global product distribution and technical services. These financial and operational metrics indicate that Rapid Micro Biosystems functions as a mid-sized specialized manufacturer, possessing a revenue base of $33.59M that supports its role in a critical but niche segment of the medical technology supply chain. The combination of a modest market cap with a specialized global footprint suggests the company occupies a focused position rather than a dominant market share, relying on high-margin potential in contamination detection to drive its specific business model.
Financial Health
The company reported annual revenue of $33.59M over the trailing twelve months, yet generated a net income of $-47,123,000, revealing a significant gap between top-line sales and bottom-line profitability that highlights an aggressive or strained cost structure. This negative net income is further reflected in an EBITDA of $-44,640,000, indicating that operating expenses substantially exceed gross profits before interest and taxes. The free cash flow stands at $-15,771,250, which signifies a cash burn scenario that limits the company's immediate financial flexibility and necessitates reliance on existing cash reserves or external financing for operational continuity. Analysis of the three primary margins shows a gross margin of 3.1%, an operating margin of -108.2%, and a profit margin of -140.3%, collectively indicating that for every dollar of revenue, the company incurs losses at the operational and profit levels. The balance sheet shows a cash position of $38.73M against total debt of $23.87M, resulting in a debt-to-equity ratio of 71.90, which suggests a leveraged position where debt exceeds equity but is partially offset by strong cash holdings. Despite the negative earnings, the current ratio of 3.31 indicates robust short-term liquidity, suggesting the company can comfortably meet its short-term obligations with its current assets. Finally, the return on equity is -86.8% and the return on assets is -34.2%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the substantial net losses recorded in the period.
Valuation Assessment
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the Forward P/E is -2.78, implying that the market expects the company to remain unprofitable in the immediate future or that valuation is being derived through alternative methods. The price-to-book ratio stands at 2.95, indicating that the market values the company at nearly three times its net asset value, suggesting a premium assigned to its intangible assets or growth potential despite current losses. The price-to-sales ratio is 2.98 and the EV/EBITDA is -1.91, both of which serve as alternative valuation indicators that price the company based on revenue multiples and enterprise value relative to cash flows, respectively, rather than traditional earnings multiples. The stock price has fluctuated between a 52-week high of $4.94 and a 52-week low of $1.86, and without a specific current price provided in the data, the trading range defines the historical volatility envelope within which the asset has moved over the past year. The beta value of 1.39 indicates that the stock's price volatility is significantly higher than the broader market, moving with greater intensity to market swings, which amplifies both potential gains and potential losses for holders.
Growth & Income
Rapid Micro Biosystems demonstrated a revenue growth rate of 37.3% year-over-year, while earnings growth is listed as N/A due to the negative net income position, implying that top-line expansion is occurring without corresponding immediate profitability improvements. As a non-dividend payer, the company does not distribute a dividend yield, and the payout ratio is 0.0%, meaning that all generated cash flow is theoretically available for reinvestment or debt reduction rather than distribution to shareholders. The absence of a dividend yield and the 0.0% payout ratio confirm that the company reinvests its financial resources directly into operations, R&D, or working capital to fuel the observed revenue growth rather than providing income to investors. The overall growth and income profile is characterized by strong top-line expansion of 37.3% coupled with a lack of current earnings growth and no dividend distribution, positioning the company as a high-risk, high-revenue-growth play where investor returns are derived solely from potential future capital appreciation.